Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Learning Approaches
100%
Enzyme Discovery
100%
Monte Carlo Learning
100%
Reversible Jump Markov Chain Monte Carlo (RJMCMC)
100%
Mycobacterium Tuberculosis (M. tb)
50%
Mathematical Model
50%
Model Order
50%
Escherichia Coli
50%
Classification Problem
50%
Saccharomyces Cerevisiae
50%
Biological Evidence
50%
Performance Prediction
50%
Full Bayesian
50%
Regression Model
50%
Accurate Reconstruction
50%
Vibrio Cholerae
50%
Bayesian Methods
50%
Bayesian Modeling
50%
Nonlinear Term
50%
Learning Techniques
50%
Eukaryotic Organisms
50%
Linear Term
50%
Bayesian Learning
50%
Radial Basis Network
50%
Metabolic Network
50%
Metabolic Reactions
50%
Caulobacter
50%
Complete Reconstruction
50%
Computational Identification
50%
Predictive Methods
50%
Least Squares Support Vector Regression (LSSVR)
50%
Engineering
Mathematical Model
100%
Classification Problem
100%
Support Vector Machine
100%
Bayesian Model
100%
Metabolic Reaction
100%
Prediction Performance
100%
Linear Term
100%
Nonlinear Term
100%
Learning Approach
100%
Learning Technique
100%
Cerevisiae
100%
Mathematics
Bayesian
100%
Markov Chain Monte Carlo
100%
Support Vector Machine
50%
Regression Model
50%
Classification Problem
50%
Mathematical Modeling
50%
Cholera
50%
Linear Term
50%
Bayesian Model
50%
Nonlinear Term
50%
Computer Science
Learning Approach
100%
markov chain monte-carlo
100%
Classification Problem
50%
Support Vector Regression
50%
Predictive Method
50%
Learning Technique
50%
Bayesian Learning
50%
Prediction Performance
50%
Radial Basis Network
50%
Bayesian Model
50%
Pharmacology, Toxicology and Pharmaceutical Science
Mycobacterium Tuberculosis
100%
Escherichia coli
100%
Vibrio Cholerae
100%
baker's yeast
100%
Caulobacter
100%
Biochemistry, Genetics and Molecular Biology
Enzyme
100%
Support Vector Machine
20%
Escherichia coli
20%
baker's yeast
20%
Mycobacterium Tuberculosis
20%
Reconstruction
20%
Vibrio Cholerae
20%
Caulobacter
20%
Metabolic Network
20%
Bayesian Learning
20%
Biological Evidence
20%